Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW28012 in Metastatic Pancreatic Cancer
NCT07707674Phase 1Not yet recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of xnw28012 in pancreatic cancer (PC) (2 arms), sponsored by Evopoint Biosciences. Primary endpoints: Incidence of Adverse Events and Incidence of Serious Adverse Events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
xnw28012
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07707674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707674.